C ongenital heart disease (CHD) has been associated with poor fetal growth (1, 2) . Distinct patterns of newborn anthropometry have been described in specific CHD lesions, likely secondary to alterations in circulatory physiology. For instance, a greater head volume as compared with birth weight in case of coarctation of aorta and a disproportionately smaller head volume as compared with birth weight in case of hypoplastic left heart syndrome (HLHS) (2) . Previous data also suggest a decrease in the growth velocity during pregnancy in the fetus with HLHS and other single ventricle (SV) defects (3, 4) . However, the fetal trajectory of various somatic growth parameters such as estimated fetal weight (EFW), femur length (FL), head circumference (HC), and abdominal circumference (AC) has not been described for most cardiac lesions. Evidence of early growth restriction has been associated with an increased risk of adverse pregnancy outcomes, including increased perinatal mortality, lower birth weight, or increased congenital malformations (5) (6) (7) . A better understanding of in utero growth in CHD may influence obstetric decision making and antenatal care. It may also provide an insight into the circulatory pathophysiology of various lesions, beyond the single measurement of a birth weight alone.
The primary aim of this study was to describe somatic growth trajectories of fetuses with CHD. We hypothesized that (i) fetuses with CHD have differential growth in utero, as seen by a difference in the z-scores of the anthropometry parameters at serial measurements, and (ii) different categories of CHD based on physiology will demonstrate different growth curves in utero.
METHODS

Study population
This was a retrospective observational cohort study that included infants with prenatally diagnosed CHD, whose mothers' received obstetric care at the University of Cincinnati Medical Center and the Good Samaritan Hospital in Cincinnati, and fetal prenatal checks at Cincinnati Children's Hospital Medical Center between January 2000 and June 2013. Exclusion criteria included-(i) antenatal or postnatal diagnosis of known genetic anomaly or syndrome that are known to be associated with growth restriction and could be a confounder (trisomy 13, trisomy 18, trisomy 21, Turner syndrome, deletion 22q11.2), (ii) hydrops of any cause (causing potential error in correct assessment of somatic measurements), (iii) hydrocephalus of any cause (causing potential error in correct assessment of HC), and (iv) multiple gestations (to avoid confounding as duration of gestation and weight is known to be lower in these). Subjects were also excluded if a minimum of two data points of growth measurements were not available. Ethical approval was obtained from the Institute Review Board of all three involved institutes.
Data collection
Demographic characteristics of the mothers, as well as risk factors such as diabetes before and during pregnancy, preeclampsia, and smoking status were collected. EFW was calculated using the Hadlock method (1984), while fetal measurements, including FL, HC, and AC, were collected from serial obstetric ultrasounds throughout gestation (8) . Birth measurements for weight, length, HC, and presence of single umbilical artery were recorded from delivery reports. Cases of intrauterine fetal demise were included as long as at least two measurements of growth parameters were available. Gestational age was obtained from the obstetric records, as determined by the best clinical estimate that relied upon the last menstrual period when an ultrasound prior to 22 weeks was within (9) . CHD was confirmed and described using fetal echocardiography and classified based on a tri-level nomenclature previously described, incorporating the Society of Thoracic Surgeons' classification as the most specific level, level 1, and then broader levels 2 and 3 that incorporate the embryological origins (10) . For purpose of analysis, CHDs were collapsed into fewer categories, namely, SV, biventricular conotruncal, d-transposition of great arteries (d-TGA), biventricular septal defects (SD, including atrial and ventricular septal defects and atrioventricular SD), and all other CHD (Others). This categorization was performed for purposes of statistical analysis and was influenced by the physiology of blood flow and the clinical manifestation and management principles in these groups of lesions.
To standardize the fetal biometry and birth anthropometry measurements for given gestational age, z-scores were calculated. z-Score for EFW and HC were calculated using the least mean square parameters for gender-specific growth curves presented by Olsen et al. (11) , therefore gestational age was restricted to 23-41 weeks. The z-weight and z-HC at birth were plotted as the final data points when creating these curves. To compute z-scores for FL and AC, international standards for fetal growth from INTERGROWTH-21st were used and therefore early weeks of gestation were examined (12) .
Statistical analysis
Descriptive statistics were presented as frequencies and percentages for categorical and as median and interquartile range for continuous variables. If the number of missing observations for maternal-fetal risk factors was 410% of the total sample number, then an unknown category was created for analysis. Significant differences in the characteristics among CHD groups were examined by Chi-square/ Fisher's exact test for categorical variables and Kruskal-Wallis test for continuous variables. To examine growth trajectories of weight, FL, HC, and AC over time for each of the CHD type, multilevel mixed-effect modeling was carried out. Linear and quadratic models were developed, and growth trajectories for each outcome was determined by testing for significance of the linear and quadratic terms in the models. As z-scores were calculated to standardize fetal biometry and birth anthropometry measurements for given gestational age using a normal reference population, trajectories above the z-score of zero represents growth higher than normal and those below zero represents growth lower than normal reference population. Sex, pregestational diabetes, and maternal smoking were found to be significant covariates in the univariate analyses and were therefore adjusted for in the multivariable models. Results were presented as estimates and SE, with P-values indicating whether the coefficient for the linear or quadratic term for given CHD type is significantly different than zero. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). Two-sided testing was carried out and P-value ⩽ 0.05 was considered statistically significant.
RESULTS
A total of 194 newborns met inclusion criteria. The details of the diagnoses among each of the groups are shown in Supplementary Appendix S1.
The patient demographics are described in Table 1 . Significant association was observed between sex and CHD types (P = 0.02). SV and d-TGA groups had a predominance of males, and SD had a predominance of females. None of the maternal factors studied demonstrated significant association with types of CHD. The unadjusted anthropometry measurements at birth, by CHD types, are presented in Table 2 . z-Scores for weight were significantly different among CHD types. None of the other measures were significantly different.
Trajectories
The unadjusted patterns of growth curves (intrauterine to birth) for weight, FL, HC, and AC, expressed as plots of the zscores of the measurement over time of gestation, are represented in Figures 1,2,3,4 , respectively. Each figure includes the overall plot comparing different categories of CHD, as well as individual plots showing all the patients in each category of CHD. The coefficients for growth parameters by CHD type after adjusting for maternal-fetal factors are presented in Table 3 .
Weight. The growth curves for weight showed significant curvilinear negative relationship in all CHD types, except d-TGA (Figure 1) . Although the curve for d-TGA appears to have differential growth, the results, however, were not significant either in the univariate or the multivariable model. EFW was lower than the reference population before 25 weeks of gestation, with improving z-scores toward a plateau around 28-32 weeks and then again showed progressively negative z-score below the reference population, indicating resumption and persistence of differential growth with advancement of gestation into the third trimester. Similar results were present in the adjusted models. The final data value plotted for EFW is the birthweight, and the correlation between the birth weight and the last EFW was r = 0.50, Po0.001.
Femur length. Linear positive growth was observed for FL in all CHD types; however, none of the coefficients were found to be significant in the adjusted models (Figure 2) . Gestational age (weeks) Figure 2 . Growth trajectories for femur length by category of congenital heart disease. Individual figures show plots of femur length in each congenital heart disease category, with each marker representing one patient observation. (a) Growth trajectories of femur length by category of congenital heart disease, complete cohort; (b) growth trajectory of femur length in the "single ventricle" group; (c) growth trajectory of femur length in the "conotruncal defects" group; (d) growth trajectory of femur length in the d-transposition of great arteries ("d-TGA") group; (e) growth trajectory of femur length in the "septal defects" group; (f) growth trajectory of femur length in the "Others" group.
Head circumference. For all CHD types, linear negative growth curves for HC were found. In the adjusted models, coefficients remained negative and were found to be significant for SV and SD ( Figure 3) .
Abdominal circumference. The growth curves for AC showed a linear relationship with respect to gestational age and in the adjusted models results remained significant for the "Others" CHD group (Figure 4) . 
DISCUSSION
We report a distinct pattern of differential somatic growth starting in the early trimester, slowing down in the middle, and then resuming and progressing in the third trimester again, in fetuses with most types of CHD, including varieties that are classically considered simple lesions. We also found the HC growth to be significantly impaired from early gestation at o24 weeks and continue to be lower throughout gestation in the SD and SV groups. The role of biometry of the fetus and newborn in the field of CHD is evolving rapidly. Lower birth weight has been found to be associated with greater risk of poor outcomes such as death or complications following corrective cardiac surgery (5, 13) . Smaller infants with CHD are also at higher risk of adverse neurodevelopmental outcomes in the long term (4, 14) . Several studies have found a significant association between the presence of CHD and lower birth weight and intrauterine growth restriction (1,2). However, neonatal measurements are only a single point in time. In this study, 94% of subjects had at least three data points, two during fetal period and one at delivery. Understanding the in utero growth trajectory may provide additional pathophysiological insights about how the prenatal course shapes subsequent outcomes.
Along with birth weight, the prognostic role of HC throughout gestation and at birth is also a topic of significant research. A global decrease in cerebral volume in newborns with CHD has been reported in postnatal studies (15) . Hahn et al. (4) found the HC z-score in fetuses with SV CHD significantly o0 throughout gestation and noted a significant decrease in growth rate in the later gestation period between 24-29 and 34 weeks. However, the intrauterine pattern of somatic growth in fetuses with anatomically and physiologically different categories of CHD has not been previously contrasted and reported. We found a significant downtrend throughout gestation in the HC measures in the SV and SD groups. The SV group is an established high-risk group and the focus of significant ongoing neurodevelopmental outcomes' research. Our findings indicate that the SD group, with diagnoses including atrial and ventricular SD that are traditionally considered less complex, are also at significant risk for differential growth and need to be included into the realm of focused long-term neurodevelopmental monitoring.
We found significantly differential growth of EFW in all the groups of CHD except the d-TGA group. This is consistent with clinical observations that infants with d-TGA have preserved birth weight or are large for gestational age, often in the setting of maternal diabetes (1, 16) . In our study, maternal diabetes did not have a significant association with type of CHD, possibly due to smaller numbers. Hahn et al. (4) found that, in SV patients, the EFW z-score remained in the normal range until 33 weeks gestation when it dropped to o0. We observed that the EFW z-scores have an early onset of differential growth, which improves with z-score approaching toward the normal until about 30 weeks gestation, before resuming a downward slope. This coincides with the time period at which maternal-fetal monitoring is more rigorous, and more frequent checks and scans are performed on the mother-baby dyad with known CHD. This also corresponds with the time of rapid fetal growth and cardiac output demands in the normal fetus. In the setting of CHD, it appears that this acceleration of growth does not occur in the normal manner. This may also present a window of opportunity for nutritional and medical intervention to help improve the growth and maturational outcomes.
Williams et al. (17) compared fetal biometry of babies with HLHS, TGA, or tetralogy of Fallot with controls without CHD. They found that early in gestation (18-26 weeks), ) did not note any effect of the heart disease on the FL or the AC throughout gestation in their study on SV patients (4). In our study also, none of the trajectories for FL were significantly different from normal. AC trajectories for SV, conotruncal, d-TGA, and SD groups are also similar to the normal population. This suggests that the differences across subgroups, whether related to physiology, genetic etiology, or maternal factors, have less impact on linear growth, abdominal organs, and adiposity. It is unclear why the AC z-score was significantly improving throughout gestation in the "Others" group, though this was a heterogeneous group with multiple types of CHD.
We did not find any association of preeclampsia or maternal smoking with growth outcomes in fetuses with CHD. Previously, preeclampsia has been associated with intrauterine growth restriction, in the setting of dysfunctional placental vascular development and function (18) . Further, pregnancies with preeclampsia have also been reported to be associated with severe CHD (19) . Jones et al. (20) found that the placentae in infants with HLHS have significantly lower placental weight and lower terminal villous and vascular density. Cigarette smoking also has a known impact on fetal growth with selectively impaired AC and peripheral muscle mass (21) .
Our study was retrospective in nature and based on analysis of clinically reported ultrasonography findings carried out as a routine procedure and not on a predefined schedule, thus introducing possibility of measurement bias. Owing to the retrospective nature of data collection, the information available was limited by the documentation in the patient's chart. Although we collected information about hypertensive diseases of pregnancy, we did not collect information regarding structural or functional heart disease in the mother, which may confound fetal growth. As the study was carried out at a tertiary center, there may be referral bias. The final measurements of birth anthropometry are technically different from the in utero measurements, however, were analyzed together in this study. The d-TGA group showed preserved growth of EFW; however, the number of patients was small and only two patients had anthropometric data available before 30 weeks of gestation. Further, we created an "Others" group that was heterogenous as it included small numbers of patients who had diagnoses that could not be placed in any of the other groups. A larger sample size would allow creation of different groups with adequate numbers instead of having to combine these groups. When excluding patients with known genetic anomalies, we included testing carried out in the prenatal period and in the neonatal admission, but not any testing carried out later in life. Further studies tracking individual organ growth trajectories may also reveal differential growth as an important contributor to overall low EFW and growth impairment.
We identified differing growth trajectories among categories of CHD. It is unclear whether this is related to hemodynamic, genetic, or other differences in patient groups. The information may guide clinicians monitoring early fetal growth in the setting of known CHD and improve risk stratification. Furthermore, the observations may direct future research to investigate why different defects lead to these patterns and inform clinical interventions in the future.
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